5 Results for "

malignant plasma cells

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "malignant plasma cells" in MCE Product Catalog:

Cat. No.: HY-P991155
CAS No.: 2988886-91-3
Synonyms: JNJ-79635322; JNJ-5322

Target:  

CD3 TNF Receptor

Research Areas:  

Cancer

Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma .
loading...
    loading...
Cat. No.: HY-177632
CAS No.: 2304711-81-5
Synonyms: ION-935918; ION251
Target:  

IFNAR

Research Areas:  

Cancer

Frenlosirsen (ION-935918; ION251) is an antisense oligonucleotide and also an IRF4 inhibitor. Frenlosirsen inhibits the survival of malignant plasma cells, reduces the burden of myeloma progenitor cells and prevents disease recurrence. Frenlosirsen is applicable to myeloma-related research .
loading...
    loading...
Cat. No.: HY-177632A
CAS No.: 2304711-82-6
Synonyms: ION-935918 sodium; ION251 sodium
Target:  

IFNAR

Research Areas:  

Cancer

Frenlosirsen sodium (ION-935918 sodium; ION251 sodium) is an antisense oligonucleotide and also an IRF4 inhibitor. Frenlosirsen sodium inhibits the survival of malignant plasma cells, reduces the burden of myeloma progenitor cells and prevents disease recurrence. Frenlosirsen sodium is applicable to myeloma-related research .
loading...
    loading...
Cat. No.: HY-P990939
CAS No.: 2851863-52-8
Synonyms: HPN 217
Target:  

CD3

Research Areas:  

Cancer

Podentamig (HPN 217) is a trispecific construct with three binding domains, including an anti-CD3 domain for T cell activation, an anti-BCMA domain for binding to plasma cells, and an anti-albumin domain for half-life extension. Podentamig is applicable to research related to relapsed/refractory multiple myeloma .
loading...
    loading...
Cat. No.: HY-106435
CAS No.: 79955-36-5
Research Areas:  

Cancer

Cystemustine is a DNA inhibitor (a chloroethyl nitrosourea, CENU). Cystemustine can cause DNA cross-linking, thereby inhibiting the proliferation of tumor cells. Cystemustine can also exert cytotoxic effects by interfering with the cell cycle, inducing cell re-differentiation, and altering phospholipid metabolism. Cystemustine exhibits high anti-tumor activity and a relatively short plasma half-life in mice. Cystemustine can be used for the study of various malignant tumors, including melanoma, glioma, renal cancer, head and neck cancer, and colorectal cancer, etc .
loading...
    loading...